Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 30, 2015, Pages 9406-9411

  Masui, Kenta ^a,b   Tanaka, Kazuhiro ^c   Ikegami, Shiro ^a   Villa, Genaro R ^a   Yang, Huijun ^a   Yong, William H ^d   Cloughesy, Timothy F ^d   Yamagata, Kanato ^b   Arai, Nobutaka ^b   Cavenee, Webster K ^a,e   Mischel, Paul S ^a,e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c KOBE UNIVERSITY   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glioblastoma; Metabolic reprogramming; mTORC2; Rictor acetylation; Targeted therapy resistance

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACETIC ACID; ACETYL COENZYME A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; ERLOTINIB; GLUCOSE; GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RICTOR PROTEIN; UNCLASSIFIED DRUG; VOXTALISIB; ACETIC ACID DERIVATIVE; AKT1 PROTEIN, HUMAN; CARRIER PROTEIN; MULTIPROTEIN COMPLEX; RICTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; ENERGY YIELD; GENE MUTATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; NUCLEAR REPROGRAMMING; NUTRIENT AVAILABILITY; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ACETYLATION; AMINO ACID SEQUENCE; ANIMAL; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; CHEMISTRY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; MOLECULAR GENETICS; MOUSE; PROTEIN TERTIARY STRUCTURE; SCID MOUSE; SEQUENCE HOMOLOGY; TUMOR CELL LINE;

MURINAE;

ACETATES; ACETYL COENZYME A; ACETYLATION; AMINO ACID SEQUENCE; ANIMALS; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLUCOSE; HUMANS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84938153238     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1511759112     Document Type: Article

References (41)

1. Ward PS, Thompson CB (2012) Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell 21(3):297-308.
2. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324(5930):1029-1033.
3. Tong X, Zhao F, Thompson CB (2009) The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 19(1):32-37.
4. Dang CV (2012) Links between metabolism and cancer. Genes Dev 26(9):877-890.
5. Lu C, Thompson CB (2012) Metabolic regulation of epigenetics. Cell Metab 16(1):9-17.
6. Masui K, Cavenee WK, Mischel PS (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab 25(7):364-373.
7. Kaelin WG, Jr, McKnight SL (2013) Influence of metabolism on epigenetics and disease. Cell 153(1):56-69.
8. Comerford SA, et al. (2014) Acetate dependence of tumors. Cell 159(7):1591-1602.
9. Lyssiotis CA, Cantley LC (2014) Acetate fuels the cancer engine. Cell 159(7):1492-1494.
10. Mashimo T, et al. (2014) Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159(7):1603-1614.
11. Cantor JR, Sabatini DM (2012) Cancer cell metabolism: One hallmark, many faces. Cancer Discov 2(10):881-898.
12. De Berardinis RJ, Thompson CB (2012) Cellular metabolism and disease: What do metabolic outliers teach us? Cell 148(6):1132-1144.
13. Kelsey I, Manning BD (2013) mTORC1 status dictates tumor response to targeted therapeutics. Sci Signal 6(294): pe31.
14. Klempner SJ, Myers AP, Cantley LC (2013) What a tangled web we weave: Emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov 3(12):1345-1354.
15. Sivendran S, et al. (2014) Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev 40(1):190-196.
16. Derr RL, et al. (2009) Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 27(7):1082-1086.
17. Guertin DA, et al. (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15(2):148-159.
18. Tanaka K, et al. (2011) Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov 1(6):524-538.
19. Masui K, et al. (2013) mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab 18(5):726-739.
20. Cai L, Sutter BM, Li B, Tu BP (2011) Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol Cell 42(4):426-437.
21. Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and coregulates major cellular functions. Science 325(5942):834-840.
22. Zhao S, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327(5968):1000-1004.
23. Xiong Y, Guan KL (2012) Mechanistic insights into the regulation of metabolic enzymes by acetylation. J Cell Biol 198(2):155-164.
24. Lin R, et al. (2014) Acetylation control of cancer cell metabolism. Curr Pharm Des 20(15):2627-2633.
25. Glidden EJ, et al. (2012) Multiple site acetylation of Rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein. J Biol Chem 287(1):581-588.
26. Cai L, Tu BP (2011) On acetyl-CoA as a gauge of cellular metabolic state. Cold Spring Harb Symp Quant Biol 76:195-202.
27. Wang L, Du Y, Lu M, Li T (2012) ASEB: A web server for KAT-specific acetylation site prediction. Nucleic Acids Res 40 (Web Server issue):W376-W379.
28. Li T, et al. (2012) Characterization and prediction of lysine (K)-acetyl-transferase specific acetylation sites. Mol Cell Proteomics 11(1):M111.011080.
29. Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley LC (1997) Determination of the specific substrate sequencemotifs of protein kinase C isozymes. J Biol Chem 272(2):952-960.
30. Vega RB, et al. (2004) Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24(19):8374-8385.
31. Sinnett-Smith J, et al. (2014) Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: Role in mitogenic signaling. Am J Physiol Cell Physiol 306(10):C961-C971.
32. Masui K, Cloughesy TF, Mischel PS (2012) Review: Molecular pathology in adult highgrade gliomas: From molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 38(3):271-291.
33. Migita T, et al. (2008) ATP citrate lyase: Activation and therapeutic implications in non-small cell lung cancer. Cancer Res 68(20):8547-8554.
34. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
35. Wellen KE, et al. (2009) ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324(5930):1076-1080.
36. Lee JV, et al. (2014) Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab 20(2):306-319.
37. Cornago M, et al. (2014) Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis 5:e1435.
38. Sharma SV, Settleman J (2007) Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev 21(24):3214-3231.
39. Weiler M, et al. (2014) mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci USA 111(1):409-414.
40. Seyfried TN, Flores RE, Poff AM, D'Agostino DP (2014) Cancer as a metabolic disease: Implications for novel therapeutics. Carcinogenesis 35(3):515-527.
41. Mukasa A, et al. (2010) Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci USA 107(6):2616-2621.